UMeWorld Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- UMeWorld Limited (Ticker: UMEWF) develops and commercializes advanced health and wellness technologies, focusing on bioresonance and non-invasive therapeutic devices. The company offers core products including the UME Master Diagnostic and Therapy System, which utilizes bioresonance technology for health diagnostics and treatments; the UME-USB and UME-USB Pro portable bioresonance devices for personal and professional use; and associated software platforms for data analysis and therapy customization, targeting practitioners in naturopathy, alternative medicine, and wellness sectors. UMeWorld operates primarily in Europe and North America, with headquarters in Paphos, Cyprus, where it was founded in 2020 as a holding company for global health tech initiatives. The company's product portfolio emphasizes bioresonance-based solutions, such as frequency therapy modules for detoxification, pain management, and immune support; proprietary algorithms for personalized health scans; and training programs for certified therapists worldwide. Services extend to research and development collaborations, device certification support, and subscription-based software updates for ongoing therapeutic advancements. UMeWorld serves individual consumers, clinics, and distributors in the alternative health industry, with expanding presence in Asia-Pacific markets through strategic reseller networks. In recent developments, UMeWorld announced a major partnership in early 2025 with European wellness distributors to accelerate UME-USB Pro adoption across 15 countries, enhancing market penetration. The company completed a funding round in late 2024, securing capital for R&D expansion into AI-integrated bioresonance analytics, with pilot launches reported in Q3 2025. Additionally, UMeWorld reorganized its subsidiary structure in mid-2025 to streamline international operations, including a new U.S. distribution hub, positioning it for scaled growth amid rising demand for non-pharmaceutical health solutions.
UMeWorld Reports Q2 FY2026 Results and Advances Scalable SAF Feedstock Strategy Through Its SCO Initiative
Comparing Relx (NYSE:RELX) & UMeWorld (OTCMKTS:UMEWF)
UMeWorld Inc. Completes Phase I PTU Process Design for Project Verdant and Advances Development and Financing Initiatives
UMeWorld Limited Outlines Strategy 2026: Scaling Global Biofuel Infrastructure and Functional Nutrition Platforms
Contrasting Tucows (NASDAQ:TCX) & UMeWorld (OTCMKTS:UMEWF)
UMeWorld Provides Corporate Update: DAGola Oils Now Bottled in the USA, Launches New Product for High-Performance Kitchens
UMeWorld Expands DAGola Line: Redefining Premium Cooking Oils with Health, Flavor, and Culinary Excellence
UMeWorld Announces Strategic Expansion in the U.S. and Forecasts Significant Revenue Growth
UMeWorld to Debut the World's First & Only Weight Loss Cooking Oil in the US
UMeWorld Limited Executing Key Acquisition Corporate Actions
UMeWorld To Continue Aggressive Expansion Strategy, Capitalizing On Innovations To Expand Edible Oils Segment